Corporate Presentation Transforming Discovery Research into - - PowerPoint PPT Presentation
Corporate Presentation Transforming Discovery Research into Innovative Medicines through Value-Based Partnership CreaGen, Inc. 299 Washington Street Woburn, MA 01801 CreaGen, Inc. Our Goal is to Create A New Generation of Small
Transforming Discovery Research into Innovative Medicines through Value-Based Partnership
2
3
Established in 2003 Corporate Headquarters: 299 Washington Street, Woburn, MA Scientists: Fifteen experienced chemists total, many with more than ten
Existing laboratories: ~ 25,000 sq feet: newly expanded in January 2018 Equipment: Waters LC-MS, Varian NMR (300 MHz), Waters auto
Library accessibility: online journal subscriptions, SciFinder and
4
Raj (SB) Rajur, PhD, Founder & CEO
30 Years of academic, industrial and management experience: ArQule, Millipore, Boston College, Northeastern University, Massachusetts General Hospital and Harvard Medical School
Hwa-OK Kim, PhD, Director of Chemistry
30 Years of industrial and management experience: Aurigene Discovery Technologies, Molecumetics, Marion Merrell Dow and New Mexico State University
Venugopal Rao, PhD, Associate Director of Chemistry
20 Years of industrial and project management experience: Pharmacopeia, Microbiotix, Indian Institute of Chemical Technology,
5
Norton P. Peet, PhD,
40 Years of industrial and management experience: Aurigene Discovery Technologies, ArQule, Aventis, Marion Merrell Dow, University of Nebraska and Massachusetts Institute of Technology
Robert Perni, PhD,
30 years of industrial and management experience: Vertex Pharmaceuticals, Sirtris Pharmaceuticals, Sterling Winthrop, Avid Therapeutics, Dartmouth College, Northeastern University, University of Rochester
Mark Tebbe, PhD,
30 years of Industrial and management experience: Co-founder of Quench Bio with Atlas Venture and of Arix Bioscience, EIR at Atlas Ventures, Quartet Medicine, Forma Therapeutics, Eli Lilly, Stanford University and University of Notre Dame.
Vinod Patel, PhD,
25 years of industrial experience: Founder, TME therapeutics, Amgen, Kinetix pharmaceuticals, Sanofi-Genzyme and University of Nottingham.
6
Small Molecules, High Throughput parallel library synthesis and
purification
Lead Generation and Lead Optimization Conjugation Chemistry, Antibody Drug Conjugates (ADC) Macrocycles and Macrocyclic libraries. Cyclic peptides Nucleosides and Nucleotides, Peptides and Peptide Nucleic Acids
(PNA)
Carbohydrates and unnatural amino acids
High Throughput purification and analysis
7
CreaGen’s Competitive Advantage: Flexibility, competitive pricing and fast turnaround time Dedicated project teams and segregation of projects Special request capabilities Automated parallel synthesis and separations Customized data input and output Multiple sample delivery formats: dry, in solution, standardized
amounts/concentrations, multiple copies, etc.
8
9
CS I: Multinational Pharma (Oncology) : Lead Optimization Project requirements:
Explore new synthetic routes. Accomplishments:
CS II: Multinational Pharma : Antibody Drug Conjugates (ADC) Project requirements:
to linkers. Introduce reactive functionalities on the linker to conjugate to antibodies.
Explore new synthetic routes. Accomplishments:
molecules to conjugate to antibodies to minimize aggregation. True extension of customer’s ADC program
10
11
CS III: Biotech. (Anti-infective): NIH & funded projects: (CreaGen -subcontractor)
Project Requirements:
for the synthesis
aggressive timeline
molecules
Accomplishments:
multigram scale non-GMP compounds for in vivo tox studies CS IV: Biotech. (Anti-infective): Lead Optimization Project requirements:
Accomplishments:
CS V: NIH a) NCATS: Synthesis of commercial preclinical candidate Project requirements and accomplishments:
b) NCI: Synthesis of commercial preclinical compound Project requirements and accomplishments:
12
CS VI: Small Biotech (Diabetes): Lead Optimization Project requirements:
searches, hit-to-lead evaluation, SAR studies, lead optimization, identification and selection of high-value preclinical candidates Accomplishments:
micromolar range
Debiophama
13
Partner Biotech Multinational Pharma Small Biotech
Project
Hit to Lead Hit to Lead Optimization Exploratory to Hit/Lead
Duration
2.5 years 3.5years 2 years
FTEs involved
1~1.5 2~4 2~4 # of compounds 750 600 2500
library synthesis: Synthetic steps
1~3 6~7 5~6
Library synthesis Method
solution phase parallel synthesis solution phase parallel synthesis solution phase parallel synthesis
Qty of compounds
10-20mg Ave 50mg Ave 20mg
Qty for scaffolds /intermediates
2g to 50g 1g to 100g 1g to 30g
Purity
90 to 98% 90 to 98% 90 to 98%
Analytical data 1H NMR, 13C NMR, 2D NMR, LC-MS, HPLC, elemental analysis, HRMS etc 1H NMR, 13C NMR, LC-MS, HPLC, elemental analysis, HRMS etc 1H NMR, 13C NMR, LC-MS, HPLC, elemental analysis HRMS etc Resulted in
Lead Optimization Filed patent: _ Lead Optimization Filed patent: _ Lead Optimization 14
Partner
Therapeutic Area Lead Discovery Lead Optimization Clinical Candidate Phase I, II & III
Multinational Pharma Cancer Biotech Diabetes Biotech Anti-infective Biotech Anti-infective Biotech Cancer Biotech Cancer Biotech CNS Asian Biotech Cancer European Pharma Diabetes 15
16
18
19
20
21
22
23